首页> 美国卫生研究院文献>Aging (Albany NY) >Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
【2h】

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis

机译:输注白蛋白可降低肝硬化中明显肝性脑病的发生率和严重程度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: The role of human albumin infusion for the prevention and treatment of overt hepatic encephalopathy (HE) in liver cirrhosis remains unclear. Results: Among the 708 patients without pre-existing overt HE, albumin infusion significantly decreased the incidence of overt HE (4.20% versus 12.70%, P<0.001) and in-hospital mortality (1.70% versus 5.40%, P=0.008). Among the 182 patients with overt HE at admission or during hospitalization, albumin infusion significantly improved overt HE (84.60% versus 68.10%, P=0.009) and decreased in-hospital mortality (7.70% versus 19.80%, P=0.018). Meta-analysis of 6 studies found that albumin infusion might decrease the risk of overt HE (OR=1.63, P=0.07), but the difference was not statistically significant. Meta-analysis of 3 studies found that albumin infusion significantly improved overt HE (OR=2.40, P=0.04). Conclusions: Based on the results of our retrospective study and meta-analysis, albumin infusion might prevent from the occurrence of overt HE and improve the severity of overt HE in cirrhosis. Our retrospective study also suggested that albumin infusion improved the outcomes of cirrhotic patients regardless of overt HE. Methods: Cirrhotic patients consecutively admitted between January 2010 and June 2014 were considered in a retrospective study. A 1:1 propensity score matching analysis was performed. Additionally, publications regarding albumin infusion for the management of overt HE were systematically searched. Meta-analyses were performed by random-effect model. Odds ratio (OR) was calculated.
机译:背景:人白蛋白输注在肝硬化中预防和治疗明显肝性脑病(HE)中的作用尚不清楚。结果:在708位未曾存在明显HE的患者中,输注白蛋白显着降低了明显HE的发生率(4.20%对12.70%,P <0.001)和院内死亡率(1.70%对5.40%,P = 0.008)。在182例入院时或住院期间出现明显HE的患者中,输注白蛋白显着改善了明显HE(84.60%对68.10%,P = 0.009)并降低了院内死亡率(7.70%对19.80%,P = 0.018)。对6项研究的荟萃分析发现,输注白蛋白可能会降低明显的HE风险(OR = 1.63,P = 0.07),但差异无统计学意义。对3项研究的荟萃分析发现,输注白蛋白显着改善了明显的HE(OR = 2.40,P = 0.04)。结论:根据我们的回顾性研究和荟萃分析的结果,输注白蛋白可能会预防肝硬化中明显的HE的发生并改善肝硬化中HE的严重程度。我们的回顾性研究还表明,无论是否出现明显的HE,白蛋白输注都能改善肝硬化患者的预后。方法:回顾性研究纳入2010年1月至2014年6月期间连续入院的肝硬化患者。进行了1:1倾向得分匹配分析。另外,系统地搜索了有关白蛋白输注以治疗明显的HE的出版物。通过随机效应模型进行荟萃分析。计算赔率(OR)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号